Last Name

Tamorah R. Lewis, MD, PhD

InstitutionChildren's Mercy Kansas City
Address2401 Gillham Rd
Kansas City MO 64108
ORCID ORCID Icon0000-0003-2137-8339 Additional info
vCardDownload vCard
    Other Positions
    TitleAssociate Professor of Pediatrics
    InstitutionUniversity of Missouri-Kansas City

    TitleResearch Assistant Professor of Pediatrics
    InstitutionUniversity of Kansas Medical Center

    Collapse Biography 
    Collapse education and training
    Johns Hopkins Univ. SOM, Baltimore, MD2007M.D.
    Johns Hopkins Univ. SOM, Baltimore, MD2010Pediatric Residency
    Johns Hopkins Hospital, Baltimore, MD2014Dual fellowship - Neonatology/Clinical Pharmacology
    Bloomberg School of Public Health, Baltimore, MD2015PhD, Clinical Investigation

    Collapse Overview 

    Collapse Research 
    Collapse research overview
    Dr. Lewis is a neonatologist and translational researcher in neonatal and perinatal Pharmacology. As an Associate Professor in the Department of Pediatrics at The University of Missouri, Kansas City School of Medicine, she is a physician scientist, spending 25% of her time as an attending in our Level IV NICU and 75% of her time designing, implementing and managing clinical research programs in neonatal pharmacology at Children’s Mercy Hospital. The overarching goal of her research program is to bring precision therapeutics to the NICU population using modern pharmacology tools. The research program focuses on pharmacokinetics, pharmacodynamics and pharmacogenetics of both old and new drugs used to treat neonatal disease, with an emphasis on optimizing and individualizing drug therapy in neonates.

    Dr. Lewis has established the Maternal Neonatal Pharmacogenetic Repository at Children’s Mercy Hospital and has multiple prospective pharmacogenetic cohort studies enrolling and depositing diverse samples to this repository. In addition, she is the recipient of a K23 from NICHD and the Robert Wood Johns Harold Amos Career Development award, both supporting ongoing neonatal pharmacology research.

    Please feel free to contact her if interested in developmental pharmacology research.
    Collapse research activities and funding
    1K23HD09136201A1     (Tamorah Lewis)Sep 1, 2018 - Aug 30, 2022
    Ontogeny and Genetics of NSAID Dose-Exposure Relationship in Preterm Infants
    Role Description: Develop a dose-individualization tool based on combination of in vivo PK and genetic samples and in vitro hepatic microsomal studies. In addition, understand the pharmacometabolome of NSAID response for PDA closure in preterm infants.

    Harold Amos Faculty Development Award #76230     (Tamorah Lewis)Jan 1, 2019 - Dec 31, 2022
    Robert Wood Johnson Foundation
    The effects of age and genetics on exposure to nonsteroidal anti-inflammatory drugs in premature infants

    R21HD101111     (LEWIS, TAMORAH R)Sep 1, 2020 - Aug 31, 2022
    Less Lumping, Smarter Splitting: Genomics and Metabolomics of Systemic Steroid Response in Bronchopulmonary Dysplasia
    Role: Principal Investigator

    R21HD101111     (Multi-PI: Tamorah Lewis / William Truog)Sep 1, 2020 - Aug 31, 2022
    Less Lumping, Smarter Splitting: Genomics and Metabolomics of Systemic Steroid
    Role Description: Investigate the pharmacogenomic and pharmacometabolomic underpinnings of variable steroid response in BPD.

    Collapse Bibliography 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Cherestal B, Lantos JD, Lewis T. Grappling With Racial Health Inequity in Pediatric Cardiology. Circ Cardiovasc Qual Outcomes. 2021 Oct; 14(10):e008099. PMID: 34551589.
      View in: PubMed
    2. Lewis T, Terrin N, Davis J, Michels K, Salaets T, Wade K. Inter-rater reliability of the neonatal adverse event severity scale using real-world Neonatal clinical trial data. J Perinatol. 2021 Sep 14. PMID: 34521975.
      View in: PubMed
    3. Cuna A, Lagatta JM, Savani RC, Vyas-Read S, Engle WA, Rose RS, DiGeronimo R, Logan JW, Mikhael M, Natarajan G, Truog WE, Kielt M, Murthy K, Zaniletti I, Lewis TR. Association of time of first corticosteroid treatment with bronchopulmonary dysplasia in preterm infants. Pediatr Pulmonol. 2021 Oct; 56(10):3283-3292. PMID: 34379886.
      View in: PubMed
    4. Lewis T, Truog W, Nelin L, Napolitano N, McKinney RL. Pharmacoepidemiology of Drug Exposure in Intubated and Non-Intubated Preterm Infants With Severe Bronchopulmonary Dysplasia. Front Pharmacol. 2021; 12:695270. PMID: 34354588.
      View in: PubMed
    5. Tan H, Blasco P, Lewis T, Ostmo S, Chiang MF, Campbell JP. Neurodevelopmental outcomes in preterm infants with retinopathy of prematurity. Surv Ophthalmol. 2021 Sep-Oct; 66(5):877-891. PMID: 33667496.
      View in: PubMed
    6. Truog WE, Lewis TR, Bamat NA. Pharmacologic Management of Severe Bronchopulmonary Dysplasia. Neoreviews. 2020 07; 21(7):e454-e468. PMID: 32611563.
      View in: PubMed
    7. Lewis T, Tolbert J, Jones BL. Increasing Resident Racial and Ethnic Diversity through Targeted Recruitment Efforts. J Pediatr. 2020 01; 216:4-6. PMID: 31843119.
      View in: PubMed
    8. Cammack B, Oschman A, Lewis T. Improving Recognition and Reporting of Adverse Drug Reactions in the NICU: A Quality Improvement Project. Pediatr Qual Saf. 2019 Sep-Oct; 4(5):e203. PMID: 31745506.
      View in: PubMed
    9. Lewis T, Chalise P, Gauldin C, Truog W. Pharmacometabolomics of Respiratory Phenotypic Response to Dexamethasone in Preterm Infants at Risk for Bronchopulmonary Dysplasia. Clin Transl Sci. 2019 11; 12(6):591-599. PMID: 31188532.
      View in: PubMed
    10. Lewis T, Truog W, Norberg M, Ballard PL, Torgerson D. Correction: Genetic variation in CRHR1 is associated with short-term respiratory response to corticosteroids in preterm infants at risk for bronchopulmonary dysplasia. Pediatr Res. 2019 Apr; 85(5):731. PMID: 30733615.
      View in: PubMed
    11. Lewis T. ECI biocommentary. Pediatr Res. 2019 04; 85(5):586. PMID: 30670773.
      View in: PubMed
    12. Cuna A, Lewis T, Dai H, Nyp M, Truog WE. Timing of postnatal corticosteroid treatment for bronchopulmonary dysplasia and its effect on outcomes. Pediatr Pulmonol. 2019 02; 54(2):165-170. PMID: 30537393.
      View in: PubMed
    13. Lewis T, Truog W, Norberg M, Ballard PL, Torgerson D. Genetic variation in CRHR1 is associated with short-term respiratory response to corticosteroids in preterm infants at risk for bronchopulmonary dysplasia. Pediatr Res. 2019 04; 85(5):625-633. PMID: 30467342.
      View in: PubMed
    14. Lewis T, Leeder JS. Pharmacogenomics and implementation of precision therapeutics in the neonatal ICU: a new frontier? Pharmacogenomics. 2018 11; 19(16):1231-1233. PMID: 30334480.
      View in: PubMed
    15. Lewis T, Van Haandel L, Scott A, Leeder JS. Intensive and prolonged urine collection in preterm infants reveals three distinct indomethacin metabolic patterns: potential implications for drug dosing. Pediatr Res. 2018 09; 84(3):325-327. PMID: 29967531.
      View in: PubMed
    16. Lewis T, Kuye S, Sherman A. Ursodeoxycholic acid versus phenobarbital for cholestasis in the Neonatal Intensive Care Unit. BMC Pediatr. 2018 06 20; 18(1):197. PMID: 29925342.
      View in: PubMed
    17. Lewis TR, Shelton EL, Van Driest SL, Kannankeril PJ, Reese J. Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment. Semin Fetal Neonatal Med. 2018 08; 23(4):232-238. PMID: 29510900.
      View in: PubMed
    18. Lewis T. Precision therapeutics in the NICU: why are we missing the mark? J Perinatol. 2018 05; 38(5):444-446. PMID: 29379159.
      View in: PubMed
    19. Lewis T, Dinh J, Leeder JS. Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research. Clin Pharmacol Ther. 2015 Sep; 98(3):309-20. PMID: 26058918.
      View in: PubMed
    20. Lewis T, Erfe BL, Ezell T, Gauda E. Pharmacoepidemiology of opiate use in the neonatal ICU: Increasing cumulative doses and iatrogenic opiate withdrawal. J Opioid Manag. 2015 Jul-Aug; 11(4):305-12. PMID: 26312957.
      View in: PubMed
    21. Sartori D, Lewis T, Breaud A, Clarke W. The development of a high-performance liquid chromatography-tandem mass spectrometric method for simultaneous quantification of morphine, morphine-3-ß-glucuronide, morphine-6-ß-glucuronide, hydromorphone, and normorphine in serum. Clin Biochem. 2015 Dec; 48(18):1283-90. PMID: 26118474.
      View in: PubMed
    22. McLemore GL, Lewis T, Jones CH, Gauda EB. Novel pharmacotherapeutic strategies for treatment of opioid-induced neonatal abstinence syndrome. Semin Fetal Neonatal Med. 2013 Feb; 18(1):35-41. PMID: 23059064.
      View in: PubMed
    23. Agthe AG, Kim GR, Mathias KB, Hendrix CW, Chavez-Valdez R, Jansson L, Lewis TR, Yaster M, Gauda EB. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics. 2009 May; 123(5):e849-56. PMID: 19398463.
      View in: PubMed
    Lewis's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description